Tango Therapeutics
TNGX
31 hedge funds and large institutions have $150M invested in Tango Therapeutics in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 9 closing their positions.
1% more capital invested
Capital invested by funds: $148M → $150M (+$1.3M)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
0.88% less ownership
Funds ownership: 62.41% → 61.53% (-0.88%)
14% less funds holding
Funds holding: 36 → 31 (-5)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
Southpoint Capital Advisors
New York
|
+$12.9M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$4.74M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$3.37M |
| 4 |
PVI
Pura Vida Investments
New York
|
+$1.11M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$157K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$8.9M |
| 2 |
VA
VR Adviser
New York
|
-$5.56M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.34M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.96M |
| 5 |
ACM
Altium Capital Management
New York
|
-$1.33M |
TNGX Hedge Fund Activity: Q2 2021 in Review
31 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q2 2021, worth a combined $150M — up 0.88% from $148M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of TNGX and 4 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Southpoint Capital Advisors, adding an estimated $12.9M. The largest seller was BVF Inc, exiting entirely with an estimated $8.9M sold.
- 31 institutional investors held Tango Therapeutics (TNGX) as of Q2 2021, down from 36 in Q1 2021.
- Funds reported $150M of Tango Therapeutics stock for Q2 2021, up 0.88% quarter-over-quarter.
- 4 funds opened new Tango Therapeutics positions in Q2 2021 and 9 closed out, a net change of -5 holders.
- The largest Tango Therapeutics buyer in Q2 2021 was Southpoint Capital Advisors, an estimated $12.9M added.
- The largest Tango Therapeutics seller in Q2 2021 was BVF Inc, an estimated $8.9M sold.
Based on aggregated 13F filings for Q2 2021.